Gocovri (Amantadine HCl) Patent Expiration, LOE Window & CMS Spending

Gocovri (Amantadine HCl) by Supernus: FDA Orange Book LOE 2038-08-23, 16 AB generics, $104.3M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSupernus
FDA Application & PathwayN208944 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2038-08-23
Orange Book Patents (*PED Extensions)13 patents (0 *PED)
Active AB-Rated Generic Competitors16
2024 CMS Total Public Spend$104.3M
2024 Medicare Part D Spend$99.8M
2024 Medicaid Spend$4.5M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 19.2% 2-yr change)